Introduction {#tca12951-sec-0001}
============

Lung cancer is the leading cause of cancer death worldwide.[1](#tca12951-bib-0001){ref-type="ref"} Despite complete resection as a potentially curative treatment in early stage non‐small cell lung cancer (NSCLC), many patients experience recurrence and death during follow‐up. Furthermore, patients with the same pathologic stage, the single most important prognostic factor, exhibit different recurrence and mortality rates.[2](#tca12951-bib-0002){ref-type="ref"} Thus, the identification of novel biomarkers for more precise prognostication after curative surgery in NSCLC patients would be very helpful.

The molecular mechanism associated with a connection between cellular metabolism and tumorigenesis is an active area of investigation in cancer research. The serine/threonine kinase liver kinase B1 (LKB1) is one of the recently discovered links connecting cell metabolism and cancer.[3](#tca12951-bib-0003){ref-type="ref"} LKB1, also known as serine/threonine kinase 11 (STK11), acts as a master upstream activator of AMP‐activated protein kinase (AMPK) upon metabolic stress, such as energy starvation, playing a crucial role in cell growth, polarity, and energy metabolism.[4](#tca12951-bib-0004){ref-type="ref"}, [5](#tca12951-bib-0005){ref-type="ref"} The LKB1‐AMPK pathway functions as a metabolic checkpoint in the cell, regulating cell growth and proliferation according to the availability of nutritional supplies.[6](#tca12951-bib-0006){ref-type="ref"} *LKB1* was first identified as the tumor suppressor gene associated with Peutz--Jeghers syndrome, a cancer predisposition syndrome,[7](#tca12951-bib-0007){ref-type="ref"} and its somatic mutation has been implicated in multiple sporadic cancers, including lung cancer.[8](#tca12951-bib-0008){ref-type="ref"}, [9](#tca12951-bib-0009){ref-type="ref"}, [10](#tca12951-bib-0010){ref-type="ref"}, [11](#tca12951-bib-0011){ref-type="ref"} More recent studies have suggested that LKB1 loss has a considerable impact not only on tumorigenesis, but also on cancer invasion and metastasis.[12](#tca12951-bib-0012){ref-type="ref"}, [13](#tca12951-bib-0013){ref-type="ref"} Although not yet fully elucidated, the relationship between LKB1 dependent molecular pathways and cancer may help us to better understand the pathogenesis of cancer, providing potential prognostic biomarkers or therapeutic targets.

In this study, we investigated if genetic variants in the LKB1 pathway could predict the survival outcomes of NSCLC patients undergoing surgical resection.

Methods {#tca12951-sec-0002}
=======

Study population {#tca12951-sec-0003}
----------------

A total of 782 patients with pathologic stages I, II, or IIIA (micro‐invasive N2) NSCLC who underwent curative surgical resection at Kyungpook National University Hospital (KNUH, *n* = 354) and Seoul National University Bundang Hospital (SNUBH, *n* = 428) were enrolled in this study. None of patients received chemotherapy or radiotherapy prior to surgery. Written informed consent was obtained from all patients prior to surgery at each of the participating institutions. This study was approved by and performed in accordance with the research protocol of the institutional review boards of KNUH and SNUBH.

Selection of single nucleotide polymorphisms (SNPs) and genotyping {#tca12951-sec-0004}
------------------------------------------------------------------

We searched the public SNP database (<http://www.ncbi.nlm.nih.gov/SNP>) for all SNPs in LKB1 pathway genes to collect potentially functional polymorphisms for this study. Next, using the FuncPred utility for functional SNP prediction and TagSNP utility for linkage disequilibrium (LD) tag SNP selection in the SNPinfo web server (<http://snpinfo.niehs.nih.gov/>), a total of 23 potentially functional SNPs with minor allele frequency 0.05 in the HapMap JPT data were collected after excluding those in linkage disequilibrium (*r* ^2^ ≥ 0.8). Genomic DNA was extracted from peripheral blood lymphocytes using a blood QuickGene DNA whole blood kit S (Fujifilm, Tokyo, Japan). Genotyping was performed using the MassARRAY iPLEX assay (Sequenom Inc., San Diego, CA, USA).

Statistical analysis {#tca12951-sec-0005}
--------------------

Differences in the distribution of genotypes according to clinicopathologic factors were compared using χ^2^ tests. Overall survival (OS) was measured from the date of surgery until the date of death or last follow‐up. Disease‐free survival (DFS) was estimated from the date of surgery until recurrence or death. The Kaplan--Meier method was used to calculate survival estimates. Differences in OS and DFS across different genotypes were compared by the log‐rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariate Cox proportional hazards models with adjustments for age, gender, smoking status, tumor histology, pathologic stage, and adjuvant therapy. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).

Results {#tca12951-sec-0006}
=======

Patient characteristics and clinical predictors {#tca12951-sec-0007}
-----------------------------------------------

The clinical and pathologic characteristics of the patients and association with OS and DFS are shown in Table [1](#tca12951-tbl-0001){ref-type="table"}. Univariate analysis showed that age (log‐rank *P* \[*P* ~L‐R~\] =), gender (*P* ~L‐R~ = ), smoking status (*P* ~L‐R~ = ), and pathologic stage (*P* ~L‐R~ = ) were significantly associated with OS. Only pathologic stage was significantly associated with DFS (*P* ~L‐R~ = ).

###### 

Univariate analysis of survival outcomes by clinicopathological features

                                                                  Overall survival   Disease‐free survival                                   
  --------------------------------------------------------- ----- ------------------ ----------------------- ------------- ------------ ---- -------------
  Overall                                                   782   208 (26.6)         62                                    340 (43.5)   45   
  Age (years)                                                                                                                                
  \< 65                                                     383   88 (23.0)          69                       2 × 10^−3^   162 (42.3)   48       0.14
  ≥ 65                                                      399   120 (30.1)         55                                    178 (44.6)   41   
  Gender                                                                                                                                     
  Male                                                      572   173 (30.2)         59                       4 × 10^−4^   261 (45.6)   42       0.10
  Female                                                    210   35 (16.7)          71                                    79 (37.6)    52   
  Smoking status                                                                                                                             
  Never                                                     232   40 (17.2)          74                       3 × 10^−4^   90 (38.8)    50       0.15
  Ever                                                      550   168 (30.6)         57                                    250 (45.5)   43   
  Histological type                                                                                                                          
  SCC                                                       341   103 (30.2)         60                          0.17      146 (42.8)   48       0.22
  AC                                                        425   99 (23.3)          63                                    184 (43.3)   42   
  LCC                                                       16    6 (37.5)           59                                    10 (62.5)    35   
  Pathologic stage                                                                                                                           
  I                                                         378   59 (15.6)          76                       1 × 10^−11^  107 (28.3)   60    2 x 10^−15^
  II                                                        227   81 (35.7)          52                                    116 (51.1)   39   
  IIIA                                                      177   68 (38.4)          47                                    117 (66.1)   20   
  Adjuvant therapy[§](#tca12951-note-0003){ref-type="fn"}                                                                                    
  No                                                        184   72 (39.6)          49                          0.58      102 (56.0)   37       0.36
  Yes                                                       220   77 (34.7)          50                                    131 (59.0)   25   

Row percentage.

Five year‐overall survival rate (OSR) and five‐year disease‐free survival rate (DFSR), proportion of survival derived from Kaplan--Meier analysis.

In pathologic stages II + IIIA: 182 cases received adjuvant chemotherapy alone, 11 cases received adjuvant radiotherapy alone, and 27 cases received both chemotherapy and radiotherapy.

AC, adenocarcinoma; LCC, large cell carcinoma; SCC, squamous cell carcinoma.

Associations between SNPs and survival outcomes {#tca12951-sec-0008}
-----------------------------------------------

The SNP information, genotype distribution, and log‐rank *P* values for OS and DFS of the 23 SNPs are shown in Table [2](#tca12951-tbl-0002){ref-type="table"}. Of the 23 SNPs analyzed, *TSC2* rs30259G \> A was significantly associated with poor OS (adjusted HR \[aHR\] 1.88, 95% CI 1.21--2.91; *P* = 0.005, under a codominant model) and DFS (aHR 1.65, 95% CI 1.15--2.38; *P* = 0.01, under a codominant model) when adjusted for age, gender, smoking status, tumor histology, pathologic stage, and adjuvant therapy (Table [3](#tca12951-tbl-0003){ref-type="table"} and Fig [1](#tca12951-fig-0001){ref-type="fig"}). The effect of the rs30259 genotypes on survival outcomes was then evaluated according to tumor histology, smoking status, and pathologic stage. rs30259G \> A was significantly associated with OS and DFS in squamous cell carcinoma (SCC) (aHR 2.36, 95% CI 1.37--4.07, *P* = 0.002; aHR 3.21, 95% CI 2.01--5.14, *P* = 1 × 10^−6^, under codominant models, respectively) but not in adenocarcinoma (AC) (Table [3](#tca12951-tbl-0003){ref-type="table"} and Fig [1](#tca12951-fig-0001){ref-type="fig"}). When stratified according to smoking status, SNPs were significantly associated with OS and DFS in ever‐smokers (aHR 2.08, 95% CI 1.30--3.32, *P* = 0.002; aHR 2.07, 95% CI 1.38--3.12, *P* = 5 × 10^−4^, under codominant models, respectively), but not in never‐smokers (Table [S1](#tca12951-supitem-0001){ref-type="supplementary-material"} and Figure [S1](#tca12951-supitem-0002){ref-type="supplementary-material"}). We then evaluated the effect of SNPs according to pathologic stage. The association between SNPs and survival outcomes remained significant in stage I (aHR 2.30, 95% CI 1.21--4.39, *P* = 0.01; aHR 2.02, 95% CI 1.13--3.60, *P* = 0.02, under codominant models, respectively), but not in stage II--IIIA (Table [S1](#tca12951-supitem-0001){ref-type="supplementary-material"} and Figure [S1](#tca12951-supitem-0002){ref-type="supplementary-material"}).

###### 

List of analyzed SNPs and associations with survival outcomes

                                      *P* for overall survival[\*](#tca12951-note-0005){ref-type="fn"}   *P* [†](#tca12951-note-0007){ref-type="fn"} for disease‐free survival[\*](#tca12951-note-0005){ref-type="fn"}                               
  ------------ -------- ------ ------ ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ------- ------ ------------ ------
  rs30259      TSC2     G\>A   0.04   0.01                                                               0.15                                                                                                            0.005   0.03   8 × 10^−6^   0.01
  rs1130214    Akt1     G\>T   0.13   0.90                                                               0.65                                                                                                            0.94    0.23   0.65         0.35
  rs2494750    Akt1     A\>G   0.38   0.33                                                               0.88                                                                                                            0.61    0.33   0.56         0.36
  rs17036508   MTOR     T\>C   0.12   0.36                                                               0.97                                                                                                            0.20    0.72   0.71         0.82
  rs1135172    MTOR     C\>T   0.16   0.48                                                               0.98                                                                                                            0.60    0.22   0.51         0.29
  rs1034528    MTOR     G\>C   0.19   0.81                                                               0.35                                                                                                            0.75    0.40   0.99         0.41
  rs1057079    MTOR     A\>G   0.18   0.90                                                               0.34                                                                                                            0.79    0.19   0.97         0.29
  rs3765904    MTOR     T\>C   0.01   0.32                                                                                                                                                                               0.46    0.33                0.46
  rs11121691   MTOR     C\>T   0.07   0.97                                                               0.98                                                                                                            0.86    0.87   0.98         0.73
  rs7711806    PRKAA1   T\>C   0.24   0.50                                                               0.99                                                                                                            0.57    0.24   0.85         0.30
  rs1342382    PRKAA2   A\>T   0.25   0.93                                                               0.17                                                                                                            0.73    0.32   0.20         0.68
  rs11581010   PRKAA2   A\>G   0.11   0.88                                                               0.98                                                                                                            0.72    0.66   0.96         0.54
  rs857148     PRKAA2   G\>T   0.42   0.94                                                               0.99                                                                                                            0.85    0.81   0.96         0.82
  rs9803799    PRKAA2   T\>G   0.16   0.54                                                               0.23                                                                                                            0.98    0.43   0.71         0.63
  rs4912411    PRKAA2   C\>A   0.38   0.39                                                               0.25                                                                                                            0.25    0.47   0.06         0.18
  rs3738568    PRKAA2   T\>C   0.36   0.31                                                               0.50                                                                                                            0.35    0.26   0.28         0.21
  rs739441     TSC1     A\>G   0.26   0.12                                                               0.31                                                                                                            0.16    0.56   0.45         0.48
  rs1050700    TSC1     A\>G   0.25   0.14                                                               0.77                                                                                                            0.14    0.62   0.84         0.70
  rs2809244    TSC1     C\>A   0.39   0.47                                                               0.49                                                                                                            0.31    0.62   0.99         0.66
  rs4962225    TSC1     A\>C   0.12   0.76                                                               0.24                                                                                                            0.45    0.66   0.56         0.54
  rs2074969    TSC2     G\>C   0.22   0.92                                                               0.09                                                                                                            0.60    0.96   0.17         0.59
  rs3806317    PRKAA2   C\>T   0.12   0.71                                                               0.51                                                                                                            0.37    0.50   0.48         0.32
  rs701848     PTEN     C\>T   0.47   0.55                                                               0.89                                                                                                            0.63    0.51   0.77         0.68

*P* values calculated using multivariate Cox proportional hazard models, adjusted for age, gender, smoking status, tumor histology, pathologic stage, and adjuvant therapy.

MAF, minor allele frequency.

###### 

Overall and disease‐free survival according to *TSC2* rs30259G \> A genotypes

                                                      Overall survival   Disease‐free survival                                                                               
  --------------------------------------------------- ------------------ ----------------------- ---- -------------------- ------- ------------ ----- ---------------------- ------------
  All cases[††](#tca12951-note-0011){ref-type="fn"}                                                                                                                          
  GG                                                  715 (92.9)         184 (74.3)              63   1.00                         302 (57.8)   46    1.00                   
  GA                                                  53 (6.9)           19 (64.2)               45   1.79 (1.12--2.89)    0.02    28 (47.2)    36    1.44 (0.98--2.13)      0.07
  AA                                                  2 (0.3)            1 (50.0)                50   4.43 (0.61--32.15)   0.14    2 (0.0)      50    26.0 (6.31--107.26)    7 × 10^−6^
  Dominant                                            55 (7.1)           20 (63.6)               45   1.85 (1.16--2.94)    0.01    30 (45.5)    35    1.54 (1.06--2.25)      0.03
  Recessive                                           768 (99.7)         203 (73.6)              62   4.25 (0.59--30.86)   0.15    330 (57.0)   45    25.43 (6.17--104.86)   8 × 10^−6^
  Codominant                                                                                          1.88 (1.21--2.91)    0.005                      1.65 (1.15--2.38)      0.01
  Squamous cell carcinoma                                                                                                                                                    
  GG                                                  314 (93.2)         90 (71.3)               62   1.00                         126 (59.9)   50    1.00                   
  GA                                                  21 (6.2)           11 (47.6)               32   2.34 (1.23--4.46)    0.01    15 (28.6)    23    2.74 (1.58--4.75)      0.0003
  AA                                                  2 (0.6)            1 (50.0)                50   4.46 (0.61--32.78)   0.14    2 (0.0)      50    20.03 (4.74--84.60)    5 × 10^−5^
  Dominant                                            23 (6.8)           12 (47.8)               33   2.45 (1.32--4.54)    0.005   17 (26.1)    21    3.07 (1.82--5.16)      2 × 10^−5^
  Recessive                                           335 (99.4)         101 (69.9)              60   4.35 (0.59--31.94)   0.15    141 (57.9)   48    18.70 (4.43--78.88)    7 × 10^−5^
  Codominant                                                                                          2.36 (1.37--4.07)    0.002                      3.21 (2.01--5.14)      1 × 10^−6^
  Adenocarcinoma                                                                                                                                                             
  GG                                                  386 (92.6)         88 (77.2)               65   1.00                         166 (57.0)   43    1.00                   
  GA                                                  31 (7.4)           8 (74.2)                56   1.22 (0.59--2.54)    0.59    13 (58.1)    46    0.96 (0.55--1.70)      0.89
  AA                                                  0 (0.0)            0 (0.0)                 0    ---                  ---     ---          ---   ---                    ---
  Dominant                                            31 (7.4)           8 (74.2)                56   1.22 (0.59--2.54)    0.59    13 (58.1)    46    0.96 (0.55--1.70)      0.89
  Recessive                                           417 (100.0)        96 (77.0)               64   ---                  ---     179 (57.1)   92    ---                    ---
  Codominant                                                                                          1.16 (0.55--2.42)    0.70                       0.95 (0.54--1.68)      0.87

Column percentage.

Row percentage.

Five‐year overall survival rate (OSR) and five‐year disease‐free survival rate (DFSR), proportion of survival derived from Kaplan--Meier analysis.

Hazard ratios (HRs), 95% confidence intervals (CIs), and their corresponding *P* values were calculated using multivariate Cox proportional hazard models adjusted for age, gender, smoking status, tumor histology, pathologic stage, and adjuvant therapy for all cases, and adjusted for age, gender, smoking status, pathologic stage, and adjuvant therapy for squamous cell carcinoma and adenocarcinoma.

Genotype failures: 12 cases for rs30259.

![Overall survival according to *TSC2* rs30259G \> A genotypes in (**a**) all cases, (**b**) squamous cell carcinoma, and (**c**) adenocarcinoma, and disease‐free survival in (**d**) all cases, (**e**) squamous cell carcinoma, and (**f**) adenocarcinoma. *P* values from the multivariate Cox proportional hazard model. ![](TCA-10-335-g001.jpg "image")GG, ![](TCA-10-335-g004.jpg "image") GA, ![](TCA-10-335-g002.jpg "image") AA.](TCA-10-335-g003){#tca12951-fig-0001}

Discussion {#tca12951-sec-0009}
==========

The present study was performed to examine whether genetic variants involved in the LKB1‐dependent pathway affect the prognosis of patients with NSCLC undergoing curative surgery. Among the 23 SNPs evaluated, *TSC2* rs30259G \> A was significantly associated with survival outcomes. Subgroup analysis showed that SNPs were significantly associated with survival outcomes in SCC, ever‐smokers, and stage I, but not in AC, never‐smokers, and stage II--IIIA. These results suggest that *TSC2* rs30259G \> A may be useful to predict prognosis in patients with NSCLC, especially SCC, after curative surgery.

TSC/mammalian target of rapamycin (mTOR) signaling is one of the major downstream pathways of LKB1/AMPK and is associated with protein synthesis, cell growth, and viability.[14](#tca12951-bib-0014){ref-type="ref"} Phosphorylation of TSC2 by AMPK after ATP depletion results in activation of the TSC1:TSC2 complex, which regulates the activity of mTORC1, a complex comprised of mTOR, raptor, and mLST8.[15](#tca12951-bib-0015){ref-type="ref"}, [16](#tca12951-bib-0016){ref-type="ref"}, [17](#tca12951-bib-0017){ref-type="ref"} Several downstream effectors of mTORC1 play a key role in protein translation, angiogenesis, and autophagy.[18](#tca12951-bib-0018){ref-type="ref"}, [19](#tca12951-bib-0019){ref-type="ref"}, [20](#tca12951-bib-0020){ref-type="ref"} Thus, genetic alteration of either TSC1, TSC2, or other upstream regulators increases the level of mTOR activators, resulting in the inappropriate stimulation of protein translation and cell growth.[4](#tca12951-bib-0004){ref-type="ref"} In lung cancer, however, data regarding a pathogenic role of the TSC complex is sparse. Previous studies have shown that both the TSC1 locus (9q34) and the TSC2 locus (16p) are frequent targets of loss of heterozygosity in both lung AC and precursor lesions.[21](#tca12951-bib-0021){ref-type="ref"}, [22](#tca12951-bib-0022){ref-type="ref"} Another study suggested that TSC1 loss synergizes with the *KRAS* mutation to enhance lung tumorigenesis in mice.[23](#tca12951-bib-0023){ref-type="ref"}

Somatic mutations in the *LKB1* gene are observed in 20\~30% of white NSCLC patients, although less frequently in Asians, ranking *LKB1* as the third most frequently mutated gene in lung adenocarcinoma.[10](#tca12951-bib-0010){ref-type="ref"}, [11](#tca12951-bib-0011){ref-type="ref"} Interestingly, in our study, *TSC2* rs30259G \> A was significantly associated with survival outcomes in SCC but not in AC. A previous study showed that *TSC1* expression was significantly associated with poor survival in SCC and small cell LC, but was not observed in AC.[24](#tca12951-bib-0024){ref-type="ref"} These results suggest that genetic variations in the LKB1 pathway may have differential biological effects that could modify the clinical outcome according to the histologic subtypes of NSCLC. Recent advances in the molecular biology of lung cancer have revealed that genetic alterations in SCC and AC are markedly different, leading to the development of histology‐specific therapeutics and different clinical outcomes between SCC and AC.[25](#tca12951-bib-0025){ref-type="ref"} Therefore, the genetic biomarkers of the two different major subtypes of NSCLC may be different. Subgroup analysis by smoking status showed that the effect of *TSC2* rs30259G \> A was limited to ever‐smokers, in line with the histology‐specific effect of the variant given that SCC is a smoking‐related histological subtype of lung cancer.[26](#tca12951-bib-0026){ref-type="ref"} Further studies are needed to investigate the role of the LKB1 pathway in the development and progression of NSCLC, and also the biologic mechanism of the observed associations between the variant and survival, especially differential effects according to histologic subtypes.

In conclusion, analysis of the *TSC2* polymorphism may be useful to predict patient prognosis after surgery, thereby helping to improve therapeutic decisions for NSCLC, especially SCC. Future studies are warranted to understand the biological mechanism of our findings and to confirm our results in a larger patient cohort including diverse ethnic groups.

Disclosure {#tca12951-sec-0011}
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###### 

**Table S1.** Overall and disease‐free survival according to *TSC2* rs30259G \> A genotypes, stratified by smoking status and pathologic stage

###### 

Click here for additional data file.

###### 

**Figure S1.** Overall survival according to *TSC2* rs30259G \> A genotypes in (a) ever‐smokers, (b) never‐smokers, (c) stage I, and (d) stage II--IIIA; disease‐free survival in (e) ever‐smokers, (f) never‐smokers, (g) stage I, and (h) stage II--IIIA. *P* values from the multivariate Cox proportional hazard model.

###### 

Click here for additional data file.
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